​

Viridian Therapeutics (VRDN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

VRDN Stock Forecast

Viridian Therapeutics (VRDN) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $43.10, with a high of $50.00 and a low of $34.00. This represents a 50.59% increase from the last price of $28.62.

$10 $18 $26 $34 $42 $50 High: $50 Avg: $43.1 Low: $34 Last Closed Price: $28.62

VRDN Stock Rating

Viridian Therapeutics stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (81.25%), 3 Hold (18.75%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 3 13 Strong Sell Sell Hold Buy Strong Buy

VRDN Price Target Upside V Benchmarks

TypeNameUpside
StockViridian Therapeutics50.59%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1411
Avg Price Target$45.00$46.00$43.18
Last Closing Price$28.62$28.62$28.62
Upside/Downside57.23%60.73%50.87%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 263141--18
Feb, 263141--18
Jan, 263131--17
Dec, 253132--18
Nov, 254112--17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 26, 2026Kelly ShiJefferies$45.00$28.8056.25%57.23%
Jan 28, 2026Gavin Clark-GartnerEvercore ISI$45.00$33.1435.79%57.23%
Jan 20, 2026Gavin Clark-GartnerEvercore ISI$44.00$32.6334.85%53.74%
Jan 07, 2026UBS$50.00$30.8262.23%74.70%
Dec 03, 2025William Blair$47.00$30.4354.45%64.22%
Nov 24, 2025Truist Financial$41.00$30.3435.14%43.26%
Nov 06, 2025RBC Capital$45.00$27.5063.64%57.23%
Nov 06, 2025Goldman Sachs$40.00$28.1142.30%39.76%
Nov 05, 2025Alex ThompsonStifel Nicolaus$48.00$24.2498.02%67.71%
Oct 21, 2025Oppenheimer$36.00$24.4947.00%25.79%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 26, 2026JefferiesBuyBuyhold
Feb 26, 2026Evercore ISIOutperformOutperformhold
Jan 20, 2026Evercore ISIOutperformOutperformhold
Jan 07, 2026UBSBuyinitialise
Jan 06, 2026Cowen & Co.BuyBuyhold
Jan 06, 2026JefferiesBuyBuyhold
Dec 18, 2025Goldman SachsBuyBuyhold
Dec 03, 2025William BlairOutperforminitialise
Nov 06, 2025RBC CapitalOutperformOutperformhold
Nov 06, 2025Goldman SachsBuyBuyhold

Financial Forecast

EPS Forecast

$-250 $-190 $-130 $-70 $-10 $50 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-6.66$-3.91$-5.31$-3.98$-221.65---
Avg Forecast$-5.38$-3.56$-4.94$-4.03$-4.16$-4.21$-1.53$1.37
High Forecast$-1.14$-1.61$-4.63$-3.85$-3.61$-2.35$3.81$2.84
Low Forecast$-14.20$-9.63$-5.48$-4.17$-4.67$-6.61$-4.08$0.56
Surprise %23.79%9.83%7.49%-1.24%5228.13%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.96M$1.77M$314.00K$302.00K$70.85M---
Avg Forecast$3.00M$2.13M$373.08K$317.29K$239.29K$45.91M$333.37M$667.21M
High Forecast$6.78M$4.92M$830.41K$411.30K$435.06K$48.18M$333.37M$1.21B
Low Forecast$1.18M$1.23M$240.70K$235.03K$130.52K$43.63M$333.37M$363.93M
Surprise %-1.30%-16.72%-15.84%-4.82%29508.50%---

Net Income Forecast

$-650M $-480M $-310M $-140M $30M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-79.41M$-129.87M$-237.73M$-269.95M$-342.60M---
Avg Forecast$-240.98M$-159.21M$-237.73M$-179.56M$-185.24M$-200.63M$-134.61M$61.50M
High Forecast$-51.21M$-71.93M$-207.35M$-172.40M$-161.68M$-105.31M$170.56M$126.91M
Low Forecast$-635.58M$-431.02M$-245.13M$-186.72M$-208.80M$-295.96M$-182.64M$25.16M
Surprise %-67.05%-18.43%-50.34%84.95%---

VRDN Forecast FAQ

Is Viridian Therapeutics stock a buy?

Viridian Therapeutics stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Viridian Therapeutics is a favorable investment for most analysts.

What is Viridian Therapeutics's price target?

Viridian Therapeutics's price target, set by 16 Wall Street analysts, averages $43.1 over the next 12 months. The price target range spans from $34 at the low end to $50 at the high end, suggesting a potential 50.59% change from the previous closing price of $28.62.

How does Viridian Therapeutics stock forecast compare to its benchmarks?

Viridian Therapeutics's stock forecast shows a 50.59% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Viridian Therapeutics over the past three months?

  • March 2026: 16.67% Strong Buy, 77.78% Buy, 5.56% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 16.67% Strong Buy, 77.78% Buy, 5.56% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 17.65% Strong Buy, 76.47% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.

What is Viridian Therapeutics’s EPS forecast?

Viridian Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.21, marking a -98.10% decrease from the reported $-222 in 2025. Estimates for the following years are $-1.53 in 2027, and $1.37 in 2028.

What is Viridian Therapeutics’s revenue forecast?

Viridian Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $45.91M, reflecting a -35.20% decrease from the reported $70.85M in 2025. The forecast for 2027 is $333.37M, and $667.21M for 2028.

What is Viridian Therapeutics’s net income forecast?

Viridian Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-201M, representing a -41.44% decrease from the reported $-343M in 2025. Projections indicate $-135M in 2027, and $61.5M in 2028.